Judy Murrah
August 12th, 2024
Recent Posts
- Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
- Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
- Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
- Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3’25 Financial Results Report in Mid-August
- Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
- Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
- Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
- Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
- Applied DNA’s LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
- Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement